Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Mar 6:2020:8768954.
doi: 10.1155/2020/8768954. eCollection 2020.

Molecular Mechanisms by Which Imeglimin Improves Glucose Homeostasis

Habib Yaribeygi  1 , Mina Maleki  2 , Thozhukat Sathyapalan  3 , Tannaz Jamialahmadi  4   5 , Amirhossein Sahebkar  6   7   8
Affiliations
Review

Molecular Mechanisms by Which Imeglimin Improves Glucose Homeostasis

Habib Yaribeygi et al. J Diabetes Res. .

Abstract

Despite different classes of antidiabetic medications available for the management of patients with diabetes, efforts are underway to identify novel and safer antihyperglycemic agents with higher potency and increased tolerability. Imeglimin is a promising antidiabetic agent that has shown to have significant antihyperglycemic effects in studies, although it has not been approved yet. There is growing evidence that imeglimin improves glucose homeostasis in the diabetic milieu; however, the precise molecular mechanisms are still not elucidated. In this review, we discuss various molecular pathways by which imeglimin exerts its antihyperglycemic effects and improves glucose homeostasis in the diabetic milieu.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest in this study.

Figures

Figure 1
Figure 1
Possible molecular mechanisms by which imeglimin improves glucose homeostasis.
See this image and copyright information in PMC

References

    1. Mayer-Davis E. J., Lawrence J. M., Dabelea D., et al. Incidence trends of type 1 and type 2 diabetes among youths, 2002–2012. New England Journal of Medicine. 2017;376(15):1419–1429. doi: 10.1056/NEJMoa1610187. - DOI - PMC - PubMed
    1. Ingelfinger J. R., Jarcho J. A. Increase in the incidence of diabetes and its implications. The New England Journal of Medicine. 2017;376(15):1473–1474. doi: 10.1056/NEJMe1616575. - DOI - PubMed
    1. Forbes J. M., Cooper M. E. Mechanisms of diabetic complications. Physiological Reviews. 2013;93(1):137–188. doi: 10.1152/physrev.00045.2011. - DOI - PubMed
    1. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54(6):1615–1625. doi: 10.2337/diabetes.54.6.1615. - DOI - PubMed
    1. da Rocha Fernandes J., Ogurtsova K., Linnenkamp U., et al. IDF diabetes atlas estimates of 2014 global health expenditures on diabetes. Diabetes Research and Clinical Practice. 2016;117:48–54. doi: 10.1016/j.diabres.2016.04.016. - DOI - PubMed